stockportfolio.pro
Neurogene Inc. (NGNE)
Healthcare · Biotechnology · NasdaqGM
Neurogene Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $25.00M | $0 | $0 | $0 | $0 | $0 | $925,000 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-37.00M | $-50.18M | $-31.59M | $-69.44M | $-33.28M | $-60.69M | $-55.19M | $-36.32M | $-75.14M | $-90.35M |
| Net margin | — | — | -126.3% | — | — | — | — | — | -8123.7% | — |
Source: Neurogene Inc. SEC filings (10-K). 14 years of history available in the interactive view.
Explore 14 years of Neurogene Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track NGNE in your portfolio →
Neurogene Inc. financial history by metric
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc. — frequently asked questions
What is Neurogene Inc.'s revenue?
Neurogene Inc. (NGNE) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Neurogene Inc. profitable?
No — NGNE reported a net loss of $-90.35M in fiscal 2025.
What is NGNE's P/E ratio?
Neurogene Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Neurogene Inc. have?
As of fiscal year 2025, NGNE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Neurogene Inc.'s market cap?
Neurogene Inc. (NGNE) has a market capitalization of about $451.93M, based on the latest data in our nightly-refreshed cache.
When does Neurogene Inc.'s fiscal year end?
NGNE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Neurogene Inc.'s official SEC filings (10-K and 10-Q), covering 14 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.